Unit of Research in Medical Nutrition, Centro Médico Nacional "Siglo XXI", Mexico.
Gene. 2012 Dec 15;511(2):404-10. doi: 10.1016/j.gene.2012.09.057. Epub 2012 Oct 2.
Lipoprotein lipase (LPL) plays a pivotal role in lipid metabolism, contributes to metabolic disorders related to insulin action and body weight regulation, and is influenced by inflammation. The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor (PPAR)γ2 gene seems to influence LPL functioning, but its role in obesity and insulin resistance status, which usually coexist in the clinical setting, has not been explored. Our aim was to analyze the association of obesity and insulin resistance with adipose LPL activity and expression, and the influence of the PPARγ2 Pro12Ala polymorphism. A cross-sectional study was conducted in 58 reproductive-age women who underwent elective abdominal surgery. Free-fatty acids, glucose, insulin, and selected adipokines were measured in fasting blood samples. DNA was isolated and the polymorphism genotyped. Biopsies of abdominal subcutaneous adipose tissue obtained during surgery were used to determine enzymatic LPL activity and expression; and expression of selected cytokines. Overweight/obese women presented lower LPL activity (P=0.022) and higher circulating TNF-α (P=0.020) than controls. Insulin resistant women also showed borderline lower LPL activity than non-resistant (P=0.052), but adiposity and inflammatory molecules were comparable. Nevertheless, LPL activity was higher in Pro12Ala carriers than in non-carriers after adjusting for obesity, insulin resistance and inflammation. Likewise, adipose LPL expression was increased in carriers while expression of cytokines was decreased. Our data suggest that insulin resistance is associated with low adipose LPL activity independently of obesity, but the PPARγ2 Pro12Ala polymorphism seems to protect the LPL functioning of obese insulin resistant women, likely through regulating inflammation in adipose tissue.
脂蛋白脂肪酶(LPL)在脂质代谢中起着关键作用,与胰岛素作用和体重调节相关的代谢紊乱有关,并且受炎症影响。过氧化物酶体增殖物激活受体(PPAR)γ2 基因的 Pro12Ala 多态性似乎会影响 LPL 的功能,但它在肥胖和胰岛素抵抗状态中的作用,这两种情况通常在临床环境中同时存在,尚未得到探索。我们的目的是分析肥胖和胰岛素抵抗与脂肪 LPL 活性和表达的关系,以及 PPARγ2 Pro12Ala 多态性的影响。对 58 名接受择期腹部手术的育龄妇女进行了横断面研究。空腹血样中测量游离脂肪酸、葡萄糖、胰岛素和选定的脂肪因子。分离 DNA 并对多态性进行基因分型。手术中获得的腹部皮下脂肪组织活检用于测定酶 LPL 活性和表达;以及表达选定的细胞因子。超重/肥胖妇女的 LPL 活性较低(P=0.022),循环 TNF-α 较高(P=0.020),而对照组则较低。胰岛素抵抗妇女的 LPL 活性也略低于非抵抗妇女(P=0.052),但肥胖和炎症分子是可比的。然而,在调整肥胖、胰岛素抵抗和炎症后,Pro12Ala 携带者的 LPL 活性高于非携带者。同样,在携带者中脂肪 LPL 表达增加,而细胞因子表达减少。我们的数据表明,胰岛素抵抗与肥胖无关的脂肪 LPL 活性降低有关,但 PPARγ2 Pro12Ala 多态性似乎可以保护肥胖胰岛素抵抗妇女的 LPL 功能,可能通过调节脂肪组织中的炎症。